PHA-022121, a Selective Bradykinin-B2-Receptor Antagonist, Is Safe and Shows Rapid Oral Bioavailability in Humans
by Pharvaris | Dec 9, 2022
Latest News
- Pharvaris to Present Clinical Data of PHA121 for the Treatment of Hereditary Angioedema at the 2021 AAAAI Annual Meeting 1st February 2021
- Pharvaris Announces Phase 1 Clinical Data of PHA121, an Oral B2 Receptor Antagonist Under Development for the Treatment of Hereditary Angioedema 27th January 2021
- Pharvaris Expands Board of Directors with Appointment of David Meeker, M.D., as Chair and Robert Glassman, M.D., as Director 5th January 2021
- Pharvaris Announces $80 Million Series C Financing to Advance Novel Oral Bradykinin-B2-Receptor Antagonists for the Treatment of HAE 18th November 2020
- Pharvaris Presents Clinical Data at ACAAI 2020 Demonstrating Safety and Therapeutic Potential of Oral PHA121 for the Treatment of HAE 13th November 2020